Find all School-related info fast with the new School-Specific MBA Forum

It is currently 18 Dec 2014, 17:31

Close

GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track
Your Progress

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.

Events & Promotions

Events & Promotions in June
Open Detailed Calendar

In clinical trials of new medicines, half of the subjects

  Question banks Downloads My Bookmarks Reviews Important topics  
Author Message
TAGS:
SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1797
Location: NewJersey USA
Followers: 4

Kudos [?]: 40 [0], given: 0

In clinical trials of new medicines, half of the subjects [#permalink] New post 31 Dec 2003, 13:40
00:00
A
B
C
D
E

Difficulty:

(N/A)

Question Stats:

100% (02:59) correct 0% (00:00) wrong based on 3 sessions
18. In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance ?a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because ____.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug's safety rather than its effectiveness, all of the subjects are healthy

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
1 KUDOS received
Senior Manager
Senior Manager
User avatar
Joined: 05 May 2003
Posts: 427
Location: Aus
Followers: 2

Kudos [?]: 5 [1] , given: 0

 [#permalink] New post 31 Dec 2003, 15:57
1
This post received
KUDOS
Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested.

As per the expectation either the subjects or the experimenters should know who has been given the drug. But the experimenters come to know because of the side effects.
1 KUDOS received
Manager
Manager
User avatar
Joined: 13 Apr 2014
Posts: 71
Followers: 1

Kudos [?]: 25 [1] , given: 187

In clinical trials of new medicines, half of the subjects receive the [#permalink] New post 10 Dec 2014, 19:56
1
This post received
KUDOS
1
This post was
BOOKMARKED
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
1 KUDOS received
Manager
Manager
User avatar
Joined: 23 Oct 2014
Posts: 77
Concentration: Marketing
GMAT 1: Q48 V25
Followers: 2

Kudos [?]: 10 [1] , given: 52

Re: In clinical trials of new medicines, half of the subjects receive the [#permalink] New post 11 Dec 2014, 19:10
1
This post received
KUDOS
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______

Which one of the following, if true, most appropriately completes the explanation?

The clinical trials are designed so that no on will know which subject is given the actual drug. To complete the explanation you must find out how this design can be compromised. Essentially, find out what can alert either the subjects or the experimenters who has the real drug.

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
Bingo. If the experimenter knows what the symptoms are and the subject is exhibiting the symptoms then the experimenter will know that this subject has the real drug.

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
This actually will enforce the design. If everyone, including the subjects with the placebo, has the same results then the design holds true. There is no way to figure out who has the real drug or who has the placebo.

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
This is irrelevant. The trial's intent does nothing to compromise the design of the trial.

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
This does not compromise the design of the trial.

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
Whether or the subject is a volunteer does not compromise the design of the trial.
Senior Manager
Senior Manager
User avatar
Joined: 05 May 2003
Posts: 427
Location: Aus
Followers: 2

Kudos [?]: 5 [0], given: 0

 [#permalink] New post 31 Dec 2003, 15:15
I will go with A.
Though B seems to be close
SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1797
Location: NewJersey USA
Followers: 4

Kudos [?]: 40 [0], given: 0

 [#permalink] New post 31 Dec 2003, 15:39
Correct answer is A. I chose B. If you guys have time please justify your answers. Your reasoning ( right or wrong ) will definitely help me and others.
SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1797
Location: NewJersey USA
Followers: 4

Kudos [?]: 40 [0], given: 0

 [#permalink] New post 31 Dec 2003, 16:08
Hats off to you. Unbelievable reasoning. Fantastic explaination indeed.
Intern
Intern
avatar
Joined: 02 Dec 2014
Posts: 17
Location: Russian Federation
Concentration: General Management, Economics
GMAT 1: 590 Q39 V32
WE: Sales (Telecommunications)
Followers: 0

Kudos [?]: 0 [0], given: 28

Re: In clinical trials of new medicines, half of the subjects receive the [#permalink] New post 11 Dec 2014, 04:41
Choice A is correct. The question states " that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested". If " subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug" then initial condition is violated
Intern
Intern
avatar
Joined: 05 Aug 2013
Posts: 39
Location: India
Schools: McDonough '17
WE: Information Technology (Computer Software)
Followers: 1

Kudos [?]: 19 [0], given: 144

CAT Tests
Re: In clinical trials of new medicines, half of the subjects receive the [#permalink] New post 11 Dec 2014, 12:21
ajaym28 wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo



Can you please post OE for this question??
Re: In clinical trials of new medicines, half of the subjects receive the   [#permalink] 11 Dec 2014, 12:21
    Similar topics Author Replies Last post
Similar
Topics:
In clinical trials of new medicines, half of the subjects receive the ajaym28 0 11 Dec 2014, 19:19
The recent clinical trials have revealed that royQV 4 15 Aug 2014, 22:12
13 Experts publish their posts in the topic Editorial: In a compelling preponderance of clinical trials, avohden 19 01 Nov 2013, 12:23
In clinical trials of new medicines, half of the subjects WinWinMBA 10 25 May 2005, 08:05
The proposal to extend clinical trials, which are routinely saurya_s 13 01 Mar 2005, 09:20
Display posts from previous: Sort by

In clinical trials of new medicines, half of the subjects

  Question banks Downloads My Bookmarks Reviews Important topics  


GMAT Club MBA Forum Home| About| Privacy Policy| Terms and Conditions| GMAT Club Rules| Contact| Sitemap

Powered by phpBB © phpBB Group and phpBB SEO

Kindly note that the GMAT® test is a registered trademark of the Graduate Management Admission Council®, and this site has neither been reviewed nor endorsed by GMAC®.